NK cell-based cancer immunotherapy: from basic biology to clinical development

Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antige...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Sizhe, Galat, Vasiliy, Galat4, Yekaterina, Lee, Yoo Kyung Annie, Wainwright, Derek, Wu, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788999/
https://www.ncbi.nlm.nih.gov/pubmed/33407739
http://dx.doi.org/10.1186/s13045-020-01014-w
_version_ 1783633145941196800
author Liu, Sizhe
Galat, Vasiliy
Galat4, Yekaterina
Lee, Yoo Kyung Annie
Wainwright, Derek
Wu, Jennifer
author_facet Liu, Sizhe
Galat, Vasiliy
Galat4, Yekaterina
Lee, Yoo Kyung Annie
Wainwright, Derek
Wu, Jennifer
author_sort Liu, Sizhe
collection PubMed
description Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively unsophisticated cues for activation, NK cell has gained significant attention in the field of cancer immunotherapy. Many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy. In this review, we provide our current understandings of NK cell biology, ongoing pre-clinical and clinical development of NK cell-based therapies and discuss the progress, challenges, and future perspectives.
format Online
Article
Text
id pubmed-7788999
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77889992021-01-07 NK cell-based cancer immunotherapy: from basic biology to clinical development Liu, Sizhe Galat, Vasiliy Galat4, Yekaterina Lee, Yoo Kyung Annie Wainwright, Derek Wu, Jennifer J Hematol Oncol Review Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively unsophisticated cues for activation, NK cell has gained significant attention in the field of cancer immunotherapy. Many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy. In this review, we provide our current understandings of NK cell biology, ongoing pre-clinical and clinical development of NK cell-based therapies and discuss the progress, challenges, and future perspectives. BioMed Central 2021-01-06 /pmc/articles/PMC7788999/ /pubmed/33407739 http://dx.doi.org/10.1186/s13045-020-01014-w Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Liu, Sizhe
Galat, Vasiliy
Galat4, Yekaterina
Lee, Yoo Kyung Annie
Wainwright, Derek
Wu, Jennifer
NK cell-based cancer immunotherapy: from basic biology to clinical development
title NK cell-based cancer immunotherapy: from basic biology to clinical development
title_full NK cell-based cancer immunotherapy: from basic biology to clinical development
title_fullStr NK cell-based cancer immunotherapy: from basic biology to clinical development
title_full_unstemmed NK cell-based cancer immunotherapy: from basic biology to clinical development
title_short NK cell-based cancer immunotherapy: from basic biology to clinical development
title_sort nk cell-based cancer immunotherapy: from basic biology to clinical development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788999/
https://www.ncbi.nlm.nih.gov/pubmed/33407739
http://dx.doi.org/10.1186/s13045-020-01014-w
work_keys_str_mv AT liusizhe nkcellbasedcancerimmunotherapyfrombasicbiologytoclinicaldevelopment
AT galatvasiliy nkcellbasedcancerimmunotherapyfrombasicbiologytoclinicaldevelopment
AT galat4yekaterina nkcellbasedcancerimmunotherapyfrombasicbiologytoclinicaldevelopment
AT leeyookyungannie nkcellbasedcancerimmunotherapyfrombasicbiologytoclinicaldevelopment
AT wainwrightderek nkcellbasedcancerimmunotherapyfrombasicbiologytoclinicaldevelopment
AT wujennifer nkcellbasedcancerimmunotherapyfrombasicbiologytoclinicaldevelopment

Ejemplares similares